Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hypertension: HELP
Articles from INSERM Paris
Based on 293 articles published since 2008
||||

These are the 293 published articles about Hypertension that originated from INSERM Paris during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12
1 Guideline Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. 2017

Volpe, Massimo / Tocci, Giuliano / de la Sierra, Alejandro / Kreutz, Reinhold / Laurent, Stéphane / Manolis, Athanasios J / Tsioufis, Kostantinos. ·Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035-39, 00189, Rome, Italy. massimo.volpe@uniroma1.it. · IRCCS Neuromed, Via Atinense, 18, 86077, Pozzilli, Isernia, Italy. massimo.volpe@uniroma1.it. · Division of Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sant'Andrea Hospital, University of Rome Sapienza, Via di Grottarossa 1035-39, 00189, Rome, Italy. · IRCCS Neuromed, Via Atinense, 18, 86077, Pozzilli, Isernia, Italy. · Department of Internal Medicine, Hospital Mútua Terrassa, University of Barcelona, Plaça del Doctor Robert, 5, 08221, Terrassa, Barcelona, Spain. · Department of Clinical Pharmacology and Toxicology, Charité, Universitätsmedizin Berlin, 10117, Berlin, Germany. · Corporate Member of Freie Universität Berlin, Berlin, Germany. · Humboldt-Universität zu Berlin, Berlin, Germany. · Berlin Institute of Health, Berlin, Germany. · Department of Pharmacology and INSERM U 970, European Georges Pompidou Hospital, Université Paris-Descartes and Assistance Publique Hôpitaux de Paris, 56 rue Leblanc, 75015, Paris, France. · Department of Cardiology, Asclepeion General Hospital, Athens, Greece. · Hippokration Hospital, National and Kapodistrian University of Athens, Vas Sofias 114, 11527, Athens, Greece. ·High Blood Press Cardiovasc Prev · Pubmed #29086364.

ABSTRACT: Despite the improvements in the management of hypertension during the last three decades, it continues to be one of the leading causes of cardiovascular morbidity and mortality worldwide. Effective and sustained reductions in blood pressure (BP) reduce the incidence of myocardial infarction, stroke, congestive heart failure and cardiovascular death. However, the proportion of patients who achieve the recommended BP goal (< 140/90 mmHg) is persistently low, worldwide. Poor adherence to therapy, complex therapeutic regimens, clinical inertia, drug-related adverse events and multiple risk factors or comorbidities contribute to the disparity between the potential and actual BP control rate. Previously we published a practical therapeutic platform for the treatment of hypertension based on clinical evidence, guidelines, best practice and clinical experience. This platform provides a personalised treatment approach and can be used to improve BP control and simplify treatment. It uses long-acting, effective and well-tolerated angiotensin receptor blocker (ARB) olmesartan, in combination with a calcium channel blocker amlodipine, and/or a thiazide diuretic hydrochlorothiazide. These drugs were selected based on the availability in most European Countries of single-pill, fixed formulations in a wide range of doses for both dual- and triple-drug combinations. The platform approach could be applied to other ARBs or angiotensin-converting enzyme inhibitors available in single-pill, fixed-dose combinations. Here, we present an update, which takes into account the results of the recently published studies and extends the applicability of the platform to common conditions that are often neglected or poorly considered in clinical practice guidelines.

2 Guideline SFE/SFHTA/AFCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism. 2016

Zennaro, Maria-Christina / Jeunemaitre, Xavier. ·INSERM, U970, Paris Cardiovascular Research Center-PARCC, 56, rue Leblanc, 75015 Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Service de génétique, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, Paris, France. ·Ann Endocrinol (Paris) · Pubmed #27315758.

ABSTRACT: While the majority of cases of primary aldosteronism (PA) are sporadic, four forms of autosomal-dominant inheritance have been described: familial hyperaldosteronism (FH) types I to IV. FH-I, also called glucocorticoid-remediable aldosteronism, is characterized by early and severe hypertension, usually before the age of 20 years. It is due to the formation of a chimeric gene between the adjacent CYP11B2 and CYP11B1 genes (coding for aldosterone synthase and 11β-hydroxylase, respectively). FH-I is often associated with family history of stroke before 40years of age. FH-II is clinically and biochemically indistinguishable from sporadic forms of PA and is only diagnosed on the basis of two or more affected family members. No causal genes have been identified so far and no genetic test is available. FH-III is characterized by severe and early-onset hypertension in children and young adults, resistant to treatment and associated with severe hypokalemia. Mild forms, resembling FH-II, have been described. FH-III is due to gain-of-function mutations in the KCNJ5 gene. Recently, a new autosomal-dominant form of familial PA, FH-IV, associated with mutations in the CACNA1H gene, was described in patients with hypertension and PA before the age of 10years. In rare cases, PA may be associated with complex neurologic disorder involving epileptic seizures and cerebral palsy (Primary Aldosteronism, Seizures, and Neurologic Abnormalities [PASNA]) due to de novo germline CACNA1D mutations.

3 Guideline SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and handbook. 2016

Amar, Laurence / Baguet, Jean Philippe / Bardet, Stéphane / Chaffanjon, Philippe / Chamontin, Bernard / Douillard, Claire / Durieux, Pierre / Girerd, Xaxier / Gosse, Philippe / Hernigou, Anne / Herpin, Daniel / Houillier, Pascal / Jeunemaitre, Xavier / Joffre, Francis / Kraimps, Jean-Louis / Lefebvre, Hervé / Ménégaux, Fabrice / Mounier-Véhier, Claire / Nussberger, Juerg / Pagny, Jean-Yves / Pechère, Antoinette / Plouin, Pierre-François / Reznik, Yves / Steichen, Olivier / Tabarin, Antoine / Zennaro, Maria-Christina / Zinzindohoue, Franck / Chabre, Olivier. ·Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Unité D'hypertension Artérielle, 75098 Paris Cedex 15, France. · Service de Cardiologie, centre d'excellence en hypertension, Clinique Mutualiste de Grenoble, 38028 Grenoble, France. · Centre François Baclesse, Service de Médecine Nucléaire, 3, Avenue du Général-Harris, 14076 Caen cedex 05, France. · CHU Grenoble-Alpes, Département de Chirurgie Thoracique, Vasculaire et Endocrinienne, 38700 La Tronche, France; Université Grenoble Alpes, LADAF-Laboratoire d'Anatomie Des Alpes Françaises, UFR de Médecine, 38700 La Tronche, France. · Centre Hospitalo-Universitaire Rangueil, Service de Médecine Interne et d'Hypertension Artérielle, 31059 Toulouse, France. · Service d'endocrinologie et des maladies métaboliques, Centre Hospitalier Régional Universitaire de Lille, 59037 Lille, France. · Santé Publique et Informatique Médicale, Hôpital Européen Georges Pompidou, 20, Rue Leblanc, 75908 Paris cedex 15, France; Centre Cochrane Français, Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, 75098 Paris France. · Pôle Cœur Métabolisme, Unité de Prévention Cardiovasculaire, Groupe Hospitalier Universitaire Pitié-Salpêtrière, 83, bld de l'Hôpital, 75013 Paris, France. · Service de Cardiologie/Hypertension CHU Bordeaux, 33076 Bordeaux, France. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Unité d'Hypertension, 20, Rue Leblanc, 75908 Paris cedex 15, France. · Service de Cardiologie, Centre Hospitalier Universitaire de Poitiers, 86021 Poitiers, France. · Département des maladies rénales et métaboliques, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France. · INSERM, UMRS_970, Paris Cardiovascular Research Center, Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, 75098 Paris, France. · Centre Hospitalo-Universitaire Rangueil, Département de Radiologie, 31059 Toulouse, France. · CHU Poitiers, Hôpital Jean Bernard, Chirurgie Générale et Endocrinienne, Université de Poitiers, Faculté de Médecine, 86000 Poitiers, France. · Service d'endocrinologie, Centre Hospitalier Universitaire, 76031 Rouen, France. · Sorbonne Universités, UPMC Univ Paris 06, Faculté de Médecine, 75006 Paris, France; AP-HP, Pitié Salpétrière, Service de Chirurgie Digestive et Viscérale, 75013 Paris, France. · Service de Médecine Vasculaire et Hypertension Artérielle, Centre Hospitalier Universitaire de Lille, 59037 Lille, France. · Service de Médecine Interne (unité vasculaire et d'hypertension), Centre Hospitalier Universitaire de Lausanne, 1011 Lausanne, Switzerland. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Département de Radiologie, 20, Rue Leblanc, 75908 Paris cedex 15, France. · Unité d'Hypertension, Hopital Universitaire de Genève, 1205 Geneve, Switzerland. · Service d'Endocrinologie et Maladies Métaboliques, CHU Côte de Nacre, 14033 Caen Cedex, France. · AP-HP, hôpital Tenon, Service de Médecine Interne, 75020 Paris, France. · Service d'Endocrinologie, Hôpital Haut Lévêque, CHU de Bordeaux, Avenue de Magellan, 33600 Pessac, France. · INSERM, UMRS_970, Paris Cardiovascular Research Center, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, 75098 Paris, France. · Sorbonne Paris Cité, Université Paris Descartes, Faculté de Médecine, 75006 Paris, France. · AP-HP, HEGP, Service de Chirurgie Digestive, Générale et Cancérologique, 75015 Paris, France; Endocrinologie, Pavillon des Ecrins, Centre Hospitalier Universitaire de Grenoble, CS 10217, 38043 Grenoble Cedex 9, France. Electronic address: OlivierChabre@chu-grenoble.fr. ·Ann Endocrinol (Paris) · Pubmed #27315757.

ABSTRACT: The French Endocrinology Society (SFE) French Hypertension Society (SFHTA) and Francophone Endocrine Surgery Association (AFCE) have drawn up recommendations for the management of primary aldosteronism (PA), based on an analysis of the literature by 27 experts in 7 work-groups. PA is suspected in case of hypertension associated with one of the following characteristics: severity, resistance, associated hypokalemia, disproportionate target organ lesions, or adrenal incidentaloma with hypertension or hypokalemia. Diagnosis is founded on aldosterone/renin ratio (ARR) measured under standardized conditions. Diagnostic thresholds are expressed according to the measurement units employed. Diagnosis is established for suprathreshold ARR associated with aldosterone concentrations >550pmol/L (200pg/mL) on 2 measurements, and rejected for aldosterone concentration<240pmol/L (90pg/mL) and/or subthreshold ARR. The diagnostic threshold applied is different if certain medication cannot be interrupted. In intermediate situations, dynamic testing is performed. Genetic forms of PA are screened for in young subjects and/or in case of familial history. The patient should be informed of the results expected from medical and surgical treatment of PA before exploration for lateralization is proposed. Lateralization is explored by adrenal vein sampling (AVS), except in patients under 35 years of age with unilateral adenoma on imaging. If PA proves to be lateralized, unilateral adrenalectomy may be performed, with adaptation of medical treatment pre- and postoperatively. If PA is non-lateralized or the patient refuses surgery, spironolactone is administered as first-line treatment, replaced by amiloride, eplerenone or calcium-channel blockers if insufficiently effective or poorly tolerated.

4 Guideline 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. 2013

Anonymous5020771. ·aCentro di Fisiologia Clinica e Ipertensione, Università Milano-Bicocca; IRCSS, Istituto Auxologico Italiano, Milano, Italy bHypertension and Cardiovascular Rehabilitation Unit, KU Leuven University, Leuven, Belgium cDepartment of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland dUniversity of Valencia INCLIVA Research Institute and CIBERobn, Madrid, Spain eUniversity of Milan, Istituto Auxologico Italiano, Milan, Italy fKlinik fur Innere Medizin III, Universitaetsklinikum des Saarlandes, Homburg/Saar, Germany gGeneral Practice and Family Healthcare, Ghent University, Ghent, Belgium hCentre for Cardiovascular Prevention, Charles University Medical School I and Thomayer Hospital, Prague, Czech Republic iDepartment of Public Health, University Hospital, Ghent, Belgium jCollege of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK kCardioangiology with CCU, Department of Translational Medical Science, Federico II University Hospital, Naples, Italy lUniversity Medical Centre Utrecht, Utrecht, Netherlands mDepartment of Social and Welfare Studies, Faculty of Health Sciences, University of Linkoping, Linkoping, Sweden nCentre for Cardiovascular Sciences, University of Birmingham and SWBH NHS Trust, Birmingham, UK oDepartment of Cardiovascular Medicine, University of Munster, Germany pDepartment of Cardiology, University of Oslo, Ullevaal Hospital, Oslo, Norway qDepartment of Pharmacology and INSERM U970, European Hospital Georges Pompidou, Paris, France rCardiology Department, Asklepeion General Hospital, Athens, Greece sDepartment of Clinical Sciences, Lund University, Scania University Hospital, Malmo, Sweden tHypertension Unit, Hospital 12 de Octubre, Madrid, Spain uNephrology and Hypertension, University Hospital, Erlangen, Germany vCardiology Practice, Ostlandske Hjertesenter, Moss, Norway wNuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK xHeart Health Centre, North Estonia Medical Centre, Tallinn ·J Hypertens · Pubmed #24107724.

ABSTRACT: -- No abstract --

5 Editorial [The urgent need for organisational changes of hypertension management in France]. 2018

Denolle, Thierry / Ménard, Joël. ·Hôpital Arthur-Gardiner, 1, rue Henri-Dunant, 35800 Dinard, France. Electronic address: denolle.thierry@wanadoo.fr. · Assistance publique-Hôpitaux de Paris, hôpital européen Georges-Pompidou/Inserm, CIC1418, faculté de médecine Paris-Diderot, centre d'investigation clinique, 75015 Paris, France. ·Presse Med · Pubmed #30454578.

ABSTRACT: -- No abstract --

6 Editorial Renal denervation in hypertension: Towards a true revival? 2018

Courand, Pierre-Yves / Azizi, Michel / Lantelme, Pierre. ·Cardiology Department, European Society of Hypertension Excellence Centre, hôpital de la Croix-Rousse et hôpital Lyon Sud, hospices civils de Lyon, 69004 Lyon, France; CREATIS, CNRS UMR 5220, INSERM U1044, INSA-Lyon, université Claude-Bernard Lyon 1, hospices civils de Lyon, 69100 Lyon, France. Electronic address: pycourand@hotmail.com. · Université Paris-Descartes, 75006 Paris, France; Hypertension Department, hôpital européen Georges-Pompidou, AP-HP, 75908 Paris, France; INSERM CIC 1418, 75908 Paris, France. · Cardiology Department, European Society of Hypertension Excellence Centre, hôpital de la Croix-Rousse et hôpital Lyon Sud, hospices civils de Lyon, 69004 Lyon, France; CREATIS, CNRS UMR 5220, INSERM U1044, INSA-Lyon, université Claude-Bernard Lyon 1, hospices civils de Lyon, 69100 Lyon, France. ·Arch Cardiovasc Dis · Pubmed #30219622.

ABSTRACT: -- No abstract --

7 Editorial Resistant Hypertension and Obstructive Sleep Apnea: Is There a Specific Indication for Endovascular Renal Denervation? 2018

Azizi, Michel / Amar, Laurence / Lorthioir, Aurélien. ·From the Paris-Descartes University, F-75006 Paris, France (M.A., L.A.) michel.azizi@aphp.fr. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, F-75015 Paris, France (M.A., L.A., A.L.). · INSERM, CIC1418, F-75015 Paris, France (M.A., A.L.). · From the Paris-Descartes University, F-75006 Paris, France (M.A., L.A.). ·Hypertension · Pubmed #29941511.

ABSTRACT: -- No abstract --

8 Editorial Is Plasma Renin Activity Genetically Determined and How Much Does It Matter for Treating Hypertension? 2018

Alhenc-Gelas, Francois / Menard, Joel. ·INSERM U1138, Paris-Descartes University, Sorbonne University, France. francois.alhenc-gelas@inserm.fr. · INSERM U1138, Paris-Descartes University, Sorbonne University, France. ·Circ Genom Precis Med · Pubmed #29650769.

ABSTRACT: -- No abstract --

9 Editorial [22 key messages from the CNEMM]. 2017

Anonymous2690926. ·Inserm U1153, équipe de recherche en épidémiologie obstétricale, périnatale et pédiatrique (EPOPé), centre de recherche épidémiologie et biostatistique Sorbonne Paris Cité (CRESS), 53, avenue de l'Observatoire, 75014 Paris, France. ·Gynecol Obstet Fertil Senol · Pubmed #29113875.

ABSTRACT: -- No abstract --

10 Editorial Is 24-Hour Central Blood Pressure Superior to 24-Hour Brachial Blood Pressure for Predicting Organ Damage? 2017

Schutte, Aletta Elisabeth / Laurent, Stephane. ·From the Hypertension in Africa Research Team, MRC Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom, South Africa (A.E.S.) · and Department of Pharmacology and Hôpital Européen Georges Pompidou, Assistance-Publique Hôpitaux de Paris, Université Paris-Descartes, INSERM U970, France (S.L.). ·Hypertension · Pubmed #29061724.

ABSTRACT: -- No abstract --

11 Editorial Expertise: no longer a sine qua non for guideline authors? 2017

Messerli, Franz H / Hofstetter, Louis / Agabiti-Rosei, Enrico / Burnier, Michel / Elliott, William J / Franklin, Stanley S / Grodzicki, Tomasz / Kario, Kazuomi / Kjeldsen, Sverre E / Kostis, John B / Laurent, Stephane / Leenen, Frans H / Lund-Johansen, Per / Mancia, Giuseppe / Narkiewicz, Krzysztof / Papademetriou, Vasilios / Parati, Gianfranco / Poulter, Neil / Redon, Josep / Rimoldi, Stefano F / Ruilope, Luis M / Schiffrin, Ernesto L / Schmieder, Roland E / Schwartz, Allan B / Sever, Peter / Sowers, James R / Staessen, Jan A / Wang, Jiguang / Weber, Michael / Williams, Bryan / de Leeuw, Peter W. ·aDepartment of Cardiology and Clinical Research, Inselspital Bern, University of Bern, Bern, Switzerland bMount Sinai Icahn School of Medicine, New York, New York, USA cJagiellonian University Krakow, Kraków, Poland dDepartment of Clinical and Experimental Sciences, Clinica Medica, University of Brescia, Brescia, Italy eService de Néphrologie et Hypertension, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland fDepartment of Biomedical Sciences, Pacific Northwest University of Health Sciences, Yakima, Washington gHeart Disease Prevention Program, Division of Cardiology, Department of Medicine, C240 Medical Sciences, University of California, Irvine, California, USA hDepartment of Internal Medicine and Gerontology, Jagiellonian University Medical College, Krakow, Poland iDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan jDepartment of Cardiology, University of Oslo, Ullevaal Hospital, Oslo, Norway kCardiovascular Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA lDepartment of Pharmacology, European Georges Pompidou Hospital, Assistance Publique Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, Paris, France mHypertension Unit, University of Ottawa Heart Institute, Ottawa, Ontario, Canada nDepartment of Heart Diseases, University of Bergen, Haukeland Hospital, Bergen, Norway oUniversity of Milano-Bicocca pIRCCS Istituto Auxologico Italiano, Milan, Italy qDepartment of Hypertension and Diabetology, Medical University of Gdansk, Gdańsk, Poland rHypertension and Cardiovascular Research Clinic, Veterans Affairs and Georgetown University Medical Centers, Washington, District of Columbia, USA sDepartment of Cardiovascular, Neural and Metabolic Sciences, Ospedale S. Luca IRCCS Istituto Auxologico Italiano tDepartment of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy uImperial Clinical Trials Unit, Imperial College London, London, UK vHospital Clinico Unviersitario de Valencia, Valencia wDepartment of Nephrology, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain xDepartment of Medicine, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Québec, Canada yDepartment of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany zDivision of Nephrology and Hypertension, Department of Medicine aaAmerican Society of Hypertension, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA bbInternational Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London - Hammersmith Campus, London, UK ccDiabetes and Cardiovascular Center, University of Missouri School of Medicine ddDepartment Service, Harry S Truman Memorial Veterans Hospital eeDepartment of Medical Pharmacology and Physiology, University of Missouri School of Medicine, Columbia, Missouri, USA ffUniversity of Leuven, Leuven, Belgium ggDepartment of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China hhSUNY Downstate Medical Center, Brooklyn, New York, USA iiUniversity College London and NIHR University College London Hospitals Biomedical Research Centre, University College London, London, UK jjDepartment of Medicine, Masstricht University Medical Center, Maastricht University, Maastricht, the Netherlands. ·J Hypertens · Pubmed #28657972.

ABSTRACT: : Several sets of guidelines have been published recently and more are in the works. The very recent American College of Physicians/American Academy of Family Practitioners guidelines were put together by a set of authors and consultants without any expertise in the topic under discussion, that is, hypertension. Although we are not maintaining that all guidelines should be written exclusively by experts, complete lack of expertise among guideline authors is not acceptable.

12 Editorial Detecting Nonadherence to Antihypertensive Treatment: Any Time, Anywhere? 2017

Hamdidouche, Idir / Jullien, Vincent / Laurent, Stéphane / Azizi, Michel. ·From the Paris-Descartes University, France (V.J., M.A., S.L.) · INSERM, CIC1418, Paris, France (I.H., M.A.) · Department of Pharmacology (I.H., V.J., S.L.), Hypertension Unit (M.A.), and DHU-PARC (M.A.), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, France · and INSERM UMRS970, Paris, France (V.J., S.L.). ·Hypertension · Pubmed #28652471.

ABSTRACT: -- No abstract --

13 Editorial Is renal denervation an alternative or a complement to aldosterone antagonists in treatment of resistant hypertension? 2017

Hamdidouche, Idir / Boutouyrie, Pierre. ·Assistance-Publique Hôpitaux de Paris, Department of Pharmacology, Hôpital Européen Georges Pompidou, Paris-Descartes University, INSERM UMRS970, Paris, France. ·J Hypertens · Pubmed #28353548.

ABSTRACT: -- No abstract --

14 Editorial Aortic Stiffening, Aortic Blood Flow Reversal, and Renal Blood Flow. 2015

Laurent, Stéphane / Boutouyrie, Pierre / Mousseaux, Elie. ·From the Department of Pharmacology (S.L., P.B.) and Department of Cardiovascular Radiology (E.M.), European Georges Pompidou Hospital, Assistance Publique-Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, Paris, France. stephane.laurent@egp.aphp.fr. · From the Department of Pharmacology (S.L., P.B.) and Department of Cardiovascular Radiology (E.M.), European Georges Pompidou Hospital, Assistance Publique-Hôpitaux de Paris, Inserm UMR 970, University Paris Descartes, Paris, France. ·Hypertension · Pubmed #25916725.

ABSTRACT: -- No abstract --

15 Editorial Timing is everything in protecting the heart and lungs in a "sympathetic storm": α before β? 2014

Degos, Vincent / London, Martin J. ·From the Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, California (V.D., M.J.L.) · and INSERM, UMR 1141, Hôpital Robert Debré, Paris, France, and Department of Anesthesia and Perioperative Care, Hopital Pitié Salpetrière, Université Pierre et Marie Curie, Paris VI, Assistance Publique des Hopitaux de Paris, Paris, France (V.D.). ·Anesthesiology · Pubmed #24625471.

ABSTRACT: -- No abstract --

16 Editorial Can we learn about the hypertension-induced decline in renal function from noninvasive haemodynamics? 2014

Laurent, Stéphane / Boutouyrie, Pierre. ·Université Paris Descartes, Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, INSERM U970, Paris, France. ·J Hypertens · Pubmed #24326990.

ABSTRACT: -- No abstract --

17 Review IL-33 (Interleukin 33)/sST2 Axis in Hypertension and Heart Failure. 2018

Ghali, Rana / Altara, Raffaele / Louch, William E / Cataliotti, Alessandro / Mallat, Ziad / Kaplan, Abdullah / Zouein, Fouad A / Booz, George W. ·From the Department of Pharmacology and Toxicology, American University of Beirut Medicine Center, Lebanon (R.G., A.K., F.A.Z.). · Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Norway (R.A., W.E.L., A.C.). · KG Jebsen Center for Cardiac Research, Oslo, Norway (R.A., W.E.L., A.C.). · Department of Pathology (R.A.), School of Medicine, University of Mississippi Medical Center, Jackson. · Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, United Kingdom (Z.M.). · Institut National de la Sante et de la Recherche Medicale (Inserm), Unit 970, Paris Cardiovascular Research Center, France (Z.M.). · Department of Pharmacology and Toxicology (G.W.B.), School of Medicine, University of Mississippi Medical Center, Jackson. ·Hypertension · Pubmed #30354724.

ABSTRACT: -- No abstract --

18 Review Interaction Between Hypertension and Arterial Stiffness. 2018

Safar, Michel E / Asmar, Roland / Benetos, Athanase / Blacher, Jacques / Boutouyrie, Pierre / Lacolley, Patrick / Laurent, Stéphane / London, Gérard / Pannier, Bruno / Protogerou, Athanase / Regnault, Véronique / Anonymous1961121. ·From the Diagnosis and Therapeutics Center, Hôtel-Dieu Hospital, Paris, France (M.E.S., J.B.). · Foundation-Medical Research Institutes, Geneva, Switzerland/Beirut, Lebanon (R.A.). · Department of Geriatrics, Nancy University Hospital, Université de Lorraine, Inserm U1116, DCAC, France (A.B.). · Department of Pharmacology, Assistance Publique-Hôpitaux de Paris, Georges Pompidou European Hospital; Paris-Descartes University; PARCC-Inserm U970, Paris, France (P.B., S.L.). · Université de Lorraine, Inserm U1116, DCAC, Nancy, France (P.L., V.R.). · PARCC-Inserm U970, Paris, France (G.L., B.P.); Department of Nephrology, Manhès Hospital, Fleury-Mérogis, France (G.L., B.P.). · Cardiovascular Prevention and Research Unit, Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Greece (A.P.). ·Hypertension · Pubmed #30354723.

ABSTRACT: -- No abstract --

19 Review [Systemic safety following intravitreal injections of anti-VEGF]. 2018

Baillif, S / Levy, B / Girmens, J-F / Dumas, S / Tadayoni, R. ·Département d'ophtalmologie, hôpital Pasteur, 30, voie Romaine, 06000 Nice cedex 1, France. Electronic address: baillif.s@chu-nice.fr. · Institut des vaisseaux et du sang, département physiologie clinique, Inserm U970, hôpital Lariboisière, 75010 Paris, France. · Département d'ophtalmologie du Professeur-Sahel-&-CIC, hôpital Quinze-Vingt, 75012 Paris, France. · Clinique Nord-Vision, 59800 Lille, France. · Département d'ophtalmologie, hôpitaux de Paris, hôpital Lariboisière, 75010 Paris, France. ·J Fr Ophtalmol · Pubmed #29567019.

ABSTRACT: The goal of this manuscript is to assess data suggesting that intravitreal injection of anti-vascular endothelial growth factors (anti-VEGFs) could result in systemic adverse events (AEs). The class-specific systemic AEs should be similar to those encountered in cancer trials. The most frequent AE observed in oncology, hypertension and proteinuria, should thus be the most common expected in ophthalmology, but their severity should be lower because of the much lower doses of anti-VEGFs administered intravitreally. Such AEs have not been frequently reported in ophthalmology trials. In addition, pharmacokinetic and pharmacodynamic data describing systemic diffusion of anti-VEGFs should be interpreted with caution because of significant inconsistencies reported. Thus, safety data reported in ophthalmology trials and pharmacokinetic/pharmacodynamic data provide robust evidence that systemic events after intravitreal injection are very unlikely. Additional studies are needed to explore this issue further, as much remains to be understood about local and systemic side effects of anti-VEGFs.

20 Review Overview of aldosterone-related genetic syndromes and recent advances. 2018

Zennaro, Maria-Christina / Fernandes-Rosa, Fabio L / Boulkroun, Sheerazed. ·INSERM, UMRS_970, Paris Cardiovascular Research Center. · Université Paris Descartes, Sorbonne Paris Cité. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Genetics Department, Paris, France. ·Curr Opin Endocrinol Diabetes Obes · Pubmed #29432258.

ABSTRACT: PURPOSE OF REVIEW: Primary aldosteronism is the most common form of secondary hypertension. Early diagnosis and treatment are key to cure of hypertension and prevention of cardiovascular complications. Recent genetic discoveries have improved our understanding on the pathophysiology of aldosterone production and triggered the development of new diagnostic procedures and targeted treatments for primary aldosteronism. RECENT FINDINGS: Different inherited genetic abnormalities distinguish specific forms of familial hyperaldosteronism. Somatic mutations are found not only in aldosterone-producing adenoma (APA), leading to primary aldosteronism, but also in aldosterone producing cell clusters of normal and micronodules from image-negative adrenal glands. Genetic knowledge has allowed the discovery of surrogate biomarkers and specific pharmacological inhibitors. Ageing appears to be associated with dysregulated and relatively autonomous aldosterone production. SUMMARY: New biochemical markers and pharmacological approaches may allow preoperative identification of somatic mutation carriers and use of targeted treatments.

21 Review How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. 2018

Bulsei, Julie / Darlington, Meryl / Durand-Zaleski, Isabelle / Azizi, Michel / Anonymous1370984. ·a URC Eco IdF, Health Economics and Health Policy Research Unit , AP-HP Paris , Paris , France. · b INSERM, Centre d'Investigation Clinique , Paris , France. · c Assistance Publique-Hôpitaux de Paris, Hypertension Unit , Hôpital Européen Georges Pompidou , Paris , France. · d Paris-Descartes University, Hypertension Unit , Paris , France. ·Blood Press · Pubmed #29069927.

ABSTRACT: Whilst much uncertainty exists as to the efficacy of renal denervation (RDN), the positive results of the DENERHTN study in France confirmed the interest of an economic evaluation in order to assess efficiency of RDN and inform local decision makers about the costs and benefits of this intervention. The uncertainty surrounding both the outcomes and the costs can be described using health economic methods such as the non-parametric bootstrap. Internationally, numerous health economic studies using a cost-effectiveness model to assess the impact of RDN in terms of cost and effectiveness compared to antihypertensive medical treatment have been conducted. The DENERHTN cost-effectiveness study was the first health economic evaluation specifically designed to assess the cost-effectiveness of RDN using individual data. Using the DENERHTN results as an example, we provide here a summary of the principle methods used to perform a cost-effectiveness analysis.

22 Review Chronic kidney disease. 2017

Romagnani, Paola / Remuzzi, Giuseppe / Glassock, Richard / Levin, Adeera / Jager, Kitty J / Tonelli, Marcello / Massy, Ziad / Wanner, Christoph / Anders, Hans-Joachim. ·Department of Experimental and Biomedical Sciences "Mario Serio" and Nephrology and Dialysis Unit, Meyer Children's University Hospital, Florence, Italy. · Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy. · Department of Medicine, Unit of Nephrology and Dialysis, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. · Department of Biomedical and Clinical Science, L. Sacco, University of Milan, Milan, Italy. · Department of Medicine, David Geffen School of Medicine at UCLA, Laguna Niguel, California, USA. · Division of Nephrology, University of British Columbia, Vancouver, Canada. · European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam, The Netherlands. · Cumming School of Medicine, Division of Nephrology and Department of Community Health Sciences, University of Calgary, Alberta, Canada. · Division of Nephrology, Ambroise Paré University Hospital, Assistance Publique - Hôpitaux de Paris, University of Versailles-Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France. · INSERM U1018 Team5, Centre de Recherche en Épidémiologie et Santé des Populations (CESP), University of Versailles-Saint-Quentin-en-Yvelines, University Paris Saclay, Villejuif, France. · Department of Medicine, Division of Nephrology, University Hospital of Würzburg, Würzburg, Germany. · Medizinische Klinik and Poliklinik IV, Klinikum der Ludwig Maximilians University (LMU) München - Innenstadt, Ziemssenstr. 1, 80336 München, Germany. ·Nat Rev Dis Primers · Pubmed #29168475.

ABSTRACT: Chronic kidney disease (CKD) is defined by persistent urine abnormalities, structural abnormalities or impaired excretory renal function suggestive of a loss of functional nephrons. The majority of patients with CKD are at risk of accelerated cardiovascular disease and death. For those who progress to end-stage renal disease, the limited accessibility to renal replacement therapy is a problem in many parts of the world. Risk factors for the development and progression of CKD include low nephron number at birth, nephron loss due to increasing age and acute or chronic kidney injuries caused by toxic exposures or diseases (for example, obesity and type 2 diabetes mellitus). The management of patients with CKD is focused on early detection or prevention, treatment of the underlying cause (if possible) to curb progression and attention to secondary processes that contribute to ongoing nephron loss. Blood pressure control, inhibition of the renin-angiotensin system and disease-specific interventions are the cornerstones of therapy. CKD complications such as anaemia, metabolic acidosis and secondary hyperparathyroidism affect cardiovascular health and quality of life, and require diagnosis and treatment.

23 Review Historical evolution of ideas on eclampsia/preeclampsia: A proposed optimistic view of preeclampsia. 2017

Robillard, Pierre-Yves / Dekker, Gustaaf / Chaouat, Gérard / Scioscia, Marco / Iacobelli, Silvia / Hulsey, Thomas C. ·Service de Néonatologie. Centre Hospitalier Universitaire Sud Réunion, BP 350, 97448 Saint-Pierre Cedex, La Réunion, France; Centre d'Etudes Périnatales Océan Indien (CEPOI), Centre Hospitalier Universitaire Sud Réunion, BP 350, 97448 Saint-Pierre cedex, La Réunion, France. Electronic address: robillard.reunion@wanadoo.fr. · Department of Obstetrics & Gynaecology, University of Adelaide, Robinson Institute, Lyell McEwin Hospital, Australia. · INSERM U 976, Pavillon Bazin, Hôpital Saint-Louis, 75010, Paris, France. · Department of Obstetrics and Gynecology, Sacro Cuore don Calabria, Negrar, Verona, Italy. · Service de Néonatologie. Centre Hospitalier Universitaire Sud Réunion, BP 350, 97448 Saint-Pierre Cedex, La Réunion, France; Centre d'Etudes Périnatales Océan Indien (CEPOI), Centre Hospitalier Universitaire Sud Réunion, BP 350, 97448 Saint-Pierre cedex, La Réunion, France. · Department of Epidemiology, School of Public Health, West Virginia University, United States. ·J Reprod Immunol · Pubmed #28941881.

ABSTRACT: Eclampsia (together with epilepsy) being the first disease ever written down since the beginning of writings in mankind 5000 years ago, we will make a brief presentation of the different major steps in comprehension of Pre-eclampsia. 1) 1840. Rayer, description of proteinuria in eclampsia, 2) 1897 Vaquez, discovery of gestational hypertension in eclamptic women, 3) In the 1970's, description of the "double" trophoblastic invasion existing only in humans (Brosens & Pijnenborg,), 4) between the 1970's and the 1990's, description of preeclampsia being a couple disease. The "paternity problem" (and therefore irruption of immunology), 5) at the end of the 1980's, a major step forward: Preeclampsia being a global endothelial cell disease (glomeruloendotheliosis, hepatic or cerebral endotheliosis, HELLP, eclampsia), inflammation (J.Roberts.C Redman, R Taylor), 6) End of the 1990's: Consensus for a distinction between early onset preeclampsia EOP and late onset LOP (34 weeks gestation), EOP being rather a problem of implantation of the trophoblast (and the placenta), LOP being rather a pre-existing maternal problem (obesity, diabetes, coagulopathies etc…). LOP is predominant everywhere on this planet, but enormously predominant in developed countries: 90% of cases. This feature is very different in countries where women have their first child very young (88% of world births), where the fatal EOP (early onset) occurs in more than 30% of cases. 7) What could be the common factor which could explain the maternal global endotheliosis in EOP and LOP? Discussion about the inositol phospho glycans P type.

24 Review Antihypertensive drugs. 2017

Laurent, Stéphane. ·Department of Pharmacology and INSERM U 970, Hôpital Européen Georges Pompidou, Paris-Descartes University, Assistance Publique - Hôpitaux de Paris, 56 rue Leblanc, 75015, Paris, France. Electronic address: stephane.laurent@egp.aphp.fr. ·Pharmacol Res · Pubmed #28780421.

ABSTRACT: Successful treatment of hypertension is possible with limited side effects given the availability of multiple antihypertensive drug classes. This review describes the various pharmacological classes of antihypertensive drugs, under two major aspects: their mechanisms of action and side effects. The mechanism of action is analysed through a pharmacological approach, i.e. the molecular receptor targets, the various sites along the arterial system, and the extra-arterial sites of action, in order to better understand in which type of hypertension a given pharmacological class of antihypertensive drug is most indicated. In addition, side effects are described and explained through their pharmacological mechanisms, in order to better understand their mechanism of occurrence and in which patients drugs are contra-indicated. This review does not address the effectiveness of monotherapies in large randomized clinical trials and combination therapies, since these are the matters of other articles of the present issue. Five major pharmacological classes of antihypertensive drugs are detailed here: beta-blockers, diuretics, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and calcium channel blockers. Four additional pharmacological classes are described in a shorter manner: renin inhibitors, alpha-adrenergic receptor blockers, centrally acting agents, and direct acting vasodilators.

25 Review Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. 2017

Bardin, Thomas / Richette, Pascal. ·Université Paris Diderot, UFR médicale, Paris, France. thomas.bardin@aphp.fr. · Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Service de Rhumatologie, Paris, Cedex, France. thomas.bardin@aphp.fr. · INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France. thomas.bardin@aphp.fr. · French-Vietnamese Research Center on Gout, Ho Chi Minh City, Vietnam. thomas.bardin@aphp.fr. · Université Paris Diderot, UFR médicale, Paris, France. · Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Service de Rhumatologie, Paris, Cedex, France. · INSERM 1132, Université Paris-Diderot, Hôpital Lariboisière, Paris, France. ·BMC Med · Pubmed #28669352.

ABSTRACT: Gout, the most prevalent inflammatory arthritis worldwide, is associated with cardiovascular and renal diseases, and is an independent predictor of premature death. The frequencies of obesity, chronic kidney disease (CKD), hypertension, type 2 diabetes, dyslipidaemias, cardiac diseases (including coronary heart disease, heart failure and atrial fibrillation), stroke and peripheral arterial disease have been repeatedly shown to be increased in gout. Therefore, the screening and care of these comorbidities as well as of cardiovascular risk factors are of outmost importance in patients with gout. Comorbidities, especially CKD, and drugs prescribed for their treatment, also impact gout management. Numerous epidemiological studies have shown the association of asymptomatic hyperuricaemia with the above-mentioned diseases and cardiovascular risk factors. Animal studies have also produced a mechanistic approach to the vascular toxicity of soluble urate. However, causality remains uncertain because confounders, reverse causality or common etiological factors might explain the epidemiological results. Additionally, these uncertainties remain unsolved despite recent studies using Mendelian randomisation or therapeutic approaches. Thus, large randomised placebo-controlled trials are still needed to assess the benefits of treating asymptomatic hyperuricaemia.

Next